MePMe-seq: antibody-free simultaneous m6A and m5C mapping in mRNA by metabolic propargyl labeling and sequencing

Katja Hartstock1, Nadine A Kueck1, Petr Spacek1

  • 1Institute of Biochemistry, Faculty of Chemistry and Pharmacy, University of Münster, Corrensstraße 36, 48149, Münster, Germany.

Nature Communications
|November 7, 2023
PubMed

Insights

Researchers developed a new method using clickable SAM precursors to detect and map mRNA methylation sites, including N6-methyladenosine (m6A) and 5-methylcytidine (m5C), with single-nucleotide precision.

Area of Science:

  • Molecular Biology
  • Epigenetics
  • Biochemistry

Background:

  • Internal modifications of mRNA, primarily methylation, regulate gene expression post-transcriptionally.
  • S-adenosyl-L-methionine (SAM) is a key metabolic hub for these methylation processes.

Purpose of the Study:

  • To develop a novel method for detecting and identifying various mRNA methylation sites.
  • To enable precise mapping of methylation sites using next-generation sequencing.

Main Methods:

  • Metabolic labeling using propargyl-selenohomocysteine (PSH), a clickable SAM precursor.
  • Intracellular generation of a SAM analogue leading to propargylated nucleosides.
  • Integration with next-generation sequencing for MePMe-seq to map N6-methyladenosine (m6A) and 5-methylcytidine (m5C) sites.

Main Results:

  • Successful detection and identification of various mRNA methylation sites.
  • Single-nucleotide precision mapping of m6A and m5C sites in mRNA.
  • Distinguishing m6A from A_m and m1A sites using termination profile analysis.

Conclusions:

  • MePMe-seq overcomes limitations of previous antibody-based and sequence-motif methods.
  • Clickable SAM-based metabolic labeling facilitates joint evaluation of methylation across RNA, DNA, and proteins.